Abstract
Despite considerable progress in development of effective therapeutic means, numerous studies are indicative of the insufficient BA control level resulting in reduction of patient life quality as well as to the high risk of disease exacerbations. The major therapeutic approach aimed at achievement of control and reduction of damage from disease is anti-inflammatory therapy based on modern inhalation glucocorticosteroids (IGCC) complemented if required by long-acting beta-2-adrenergic agonists (LABA).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
